Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtend

OBJECTIVE: Fracture risk increases with age, but few studies focus on persons ≥80 years. In the ACTIVE trial, treatment with abaloparatide for 18 months reduced osteoporotic fracture risk and increased bone mineral density. These effects were maintained with 24 months alendronate treatment in ACTIVE...

Full description

Saved in:
Bibliographic Details
Published in:Menopause
Main Authors: Greenspan, Susan L., Fitzpatrick, Lorraine A., Mitlak, Bruce, Wang, Yamei, Harvey, Nicholas C., Deal, Chad, Cosman, Felicia, McClung, Michael
Format: Artigo
Language:Inglês
Published: Lippincott Williams & Wilkins 2020
Subjects:
Original Studies
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7515468/
https://ncbi.nlm.nih.gov/pubmed/32665529
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/GME.0000000000001593
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items